CL2012001128A1 -
Quinuclidine derived compounds, modulators of the alpha-7 nicotinic acetylcholine receptor; pharmaceutical composition comprising them; and use for the treatment of schizophrenia, Alzheimer's disease, cognitive disorders, rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn's disease, and diabetes.
- Google Patents
Quinuclidine derived compounds, modulators of the alpha-7 nicotinic acetylcholine receptor; pharmaceutical composition comprising them; and use for the treatment of schizophrenia, Alzheimer's disease, cognitive disorders, rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn's disease, and diabetes.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb CofiledCriticalBristol Myers Squibb Co
Priority to CL2012001128ApriorityCriticalpatent/CL2012001128A1/en
Publication of CL2012001128A1publicationCriticalpatent/CL2012001128A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
LA INVENCION PROPORCIONA COMPUESTOS DERIVADOS DE LA FORMULA IINCLUYENDO SUS SALES FARMACÉUTICAMENTE ACEPTABLES, ASÍ COMO LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS; Y EL USO DE LOS MISMOS PARA PREPARAR UN MEDICAMENTO ÚTIL EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, ESPECIALMENTE TRASTORNOS AFECTIVOS Y NEURODEGENERATIVOS COMO ESQUIZOFRENIA , ENFERMEDAD DE AIZHEIMER, ENTRE OTROS.THE INVENTION PROVIDES COMPOUNDS DERIVED FROM THE FORMULA I INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS, AS WELL AS THE PHARMACEUTICAL COMPOSITIONS INCLUDING SUCH COMPOUNDS; AND THE USE OF THE SAME TO PREPARE A USEFUL MEDICINAL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY AFFECTIVE AND NEURODEGENERATIVE DISORDERS SUCH AS SCHIZOPHRENIA, AIZHEIMER'S DISEASE, AMONG OTHERS.
CL2012001128A2012-04-272012-04-27
Quinuclidine derived compounds, modulators of the alpha-7 nicotinic acetylcholine receptor; pharmaceutical composition comprising them; and use for the treatment of schizophrenia, Alzheimer's disease, cognitive disorders, rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn's disease, and diabetes.
CL2012001128A1
(en)
Quinuclidine derived compounds, modulators of the alpha-7 nicotinic acetylcholine receptor; pharmaceutical composition comprising them; and use for the treatment of schizophrenia, Alzheimer's disease, cognitive disorders, rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn's disease, and diabetes.
Quinuclidine derived compounds, modulators of the alpha-7 nicotinic acetylcholine receptor; pharmaceutical composition comprising them; and use for the treatment of schizophrenia, Alzheimer's disease, cognitive disorders, rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn's disease, and diabetes.
Quinuclidine derived compounds, modulators of the alpha-7 nicotinic acetylcholine receptor; pharmaceutical composition comprising them; and use for the treatment of schizophrenia, Alzheimer's disease, cognitive disorders, rheumatoid arthritis, osteoarthritis, ulcerative colitis, Crohn's disease, and diabetes.
Compounds derived from quinuclidine, acetylcholine a7 receptor ligands; its pharmaceutical composition; its use for the treatment of disorders of the central nervous system, especially affective and neurodegenerative diseases such as schizophrenia and Alzheimer's.
Compounds derived from 1-arylcarbonyl-4-oxy-piperidino; pharmaceutical composition that includes them; Use for the prevention or treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease or multiple sclerosis.
Triazolone-derived compounds, such as mpges-1 inhibitors; process of preparing said compounds; pharmaceutical composition that includes them, useful for the treatment of inflammation, asthma, epoc, arthritis, parkinson's disease and autoimmune diseases, among other diseases.
Compounds derived from fused pyridine rings, btk inhibitors; pharmaceutical composition; pharmaceutical combination; and its use for btk mediated disorders such as arthritis and its variants, haematological disorders, crohn's disease, among others.
Compounds derived from heteroaryl benzenesulfonamide, modulators of nachr alfa 7; pharmaceutical composition; and its use in Alzheimer's disease, mild cognitive disorder, senile dementia, vascular dementia, among others.
Compounds derived from substituted 6,7-dialkoxy-3-isoquinolinol, inhibitors of pde10a; pharmaceutical composition that includes them; and its use in the treatment of metabolic disorders, CNS disorders such as Alzheimer's disease, dementia, depression and neurodegenerative disorders such as multiple sclerosis, among others.
Compounds derived from (pyridin-4-yl) -benzylamides as allosteric modulators of nachr alfa-7; pharmaceutical composition; process to prepare the pharmaceutical composition; and use in the treatment of diseases such as Alzheimer's, anxiety, schizophrenia, parkinson's, among others.